- Home
- ASBP vs TOVX Comparison
ASBP vs TOVX Comparison
Compare ASBP & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASBP | TOVX |
|---|---|---|
| Founded | 2021 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.4M | 11.1M |
| IPO Year | 2021 | 2012 |
Fundamental Metrics
Financial Performance| Metric | ASBP | TOVX |
|---|---|---|
| Price | $9.20 | $0.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 33.5K | ★ 325.2K |
| Earning Date | 04-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 89.07 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.05 | $0.16 |
| 52 Week High | $9.50 | $0.86 |
Technical Indicators
Market Signals| Indicator | ASBP | TOVX |
|---|---|---|
| Relative Strength Index (RSI) | 55.37 | 38.39 |
| Support Level | $7.80 | $0.17 |
| Resistance Level | $9.50 | $0.26 |
| Average True Range (ATR) | 0.65 | 0.01 |
| MACD | -0.08 | -0.00 |
| Stochastic Oscillator | 69.70 | 13.32 |
Price Performance
Historical ComparisonAbout ASBP Aspire Biopharma Holdings Inc.
Aspire Biopharma Holdings Inc is an early-stage biopharmaceutical company focused on developing and commercializing novel sublingual drug delivery technologies. The company is mainly engaged in advancing patent-pending formulations designed to enable rapid absorption of drugs, initially targeting high-dose aspirin products for cardiovascular and pain management applications. Its technology aims to improve efficacy and response time by bypassing the gastrointestinal tract through sublingual delivery.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.